A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
Authors:
Open Access
- 1 November 2016
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 9, 7095-7103
Abstract
Introduction: Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples. Methods: Using healthy donor blood spiked with human epidermal growth factor receptor 2 (HER-2)-positive breast cancer cell lines, SKBr-3 and BT-474, and a corresponding negative control (the HER-2-negative MCF-7 cell line), an in vitro CTC model system was designed. Following isolation in the CellSearch system, CTC samples were further enriched and fixed on microscope slides. Immunocytochemical staining with cytokeratin and 4',6-diamidino-2'-phenylindole dihydrochloride identified CTCs under a fluorescence microscope. A FISH-based procedure was optimized by applying the HER2 IQFISH pharmDx assay for assessment of HER-2 amplification status in breast cancer CTCs. Results: A method for defining the presence of HER-2 amplification in single breast cancer CTCs after CellSearch isolation was established using cell lines as positive and negative controls. The method was validated in blood from breast cancer patients showing that one out of six patients acquired CTC HER-2 amplification during treatment against metastatic disease. Conclusion: HER-2 amplification status of CTCs can be determined following CellSearch isolation and further enrichment. FISH is superior to protein assessment of HER-2 status in predicting response to HER-2-targeted immunotherapy in breast cancer patients. This assay has the potential of identifying patients with a shift in HER-2 status who may benefit from treatment adjustments.Keywords
This publication has 37 references indexed in Scilit:
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to TrastuzumabJapanese Journal of Clinical Oncology, 2011
- Single circulating tumor cell detection and overall survival in nonmetastatic breast cancerAnnals of Oncology, 2009
- Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsBreast Cancer Research and Treatment, 2009
- Characterization of circulating tumor cells by fluorescence in situ hybridizationCytometry Part A, 2009
- HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 2008
- uPAR and HER-2 gene status in individual breast cancer cells from blood and tissuesProceedings of the National Academy of Sciences, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- HER-2 gene amplification can be acquired as breast cancer progressesProceedings of the National Academy of Sciences, 2004